STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Signal transducers and activators of transcription (STATs) mediate essential signaling pathways in different biological processes, including immune responses, hematopoiesis, and neurogenesis. Among the STAT members, STAT3 plays crucial roles in cell proliferation, survival, and differentiation. While STAT3 activation is transient in physiological conditions, STAT3 becomes persistently activated in a high percentage of solid and hematopoietic malignancies (e.g., melanoma, multiple myeloma, breast, prostate, ovarian, and colon cancers), thus contributing to malignant transformation and progression. This makes STAT3 an attractive therapeutic target for cancers. Initial strategies aimed at inhibiting STAT3 functions have focused on blocking the action of its activating kinases or sequestering its DNA binding ability. More recently, the diffusion of proteomic-based techniques, which have allowed for the identification and characterization of novel STAT3-interacting proteins able to modulate STAT3 activity via its subcellular localization, interact with upstream kinases, and recruit transcriptional machinery, has raised the possibility to target such cofactors to specifically restrain STAT3 oncogenic functions. In this article, we summarize the available data about the function of STAT3 interactors in malignant cells and discuss their role as potential therapeutic targets for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“Notably, STAT3 was recently reported to be one of the key transcription factors involved in the formation of super-enhancers [35,36] and this further pinpoints the role of STAT3 interactome as an exceptionally interesting drug target.”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×
“Thus, disrupting the structure of such super-enhancers or inhibiting the cofactors involved in the formation of super-enhancers represents a new and promising approach for cancer therapy [33,34].”
BackgroundWen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“While physiological STAT3 activation is transient, rapidly returning to the basal state, STAT3 becomes inappropriately and persistently activated in a wide variety of hematopoietic and solid malignancies, including melanoma, multiple myeloma, breast, prostate, ovarian, and colon cancer [4], due to upregulation of upst…”
BackgroundHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 1×
“Currently, panobinostat is an approved drug for the treatment of lymphoma and multiple myeloma and a number of HDAC inhibitors are in clinical trials for the treatment of various malignancies [106].”
BackgroundThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · cited 1×
“Phosphorylated STAT3 can homodimerize, as well as form dimers with STAT1, and then move into the nucleus to exert its functions [9].”
BackgroundDangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 3×
“The first evidence of a specific STAT3 repressor comes from the work of Chung and colleagues, who identified PIAS3 in 1997 [61].”
BackgroundInfluentialStat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · cited 9×
“Yuan and coworkers demonstrated that STAT3 interacted with the Histone acetyltransferase (HAT)p300/CREB-binding protein (CBP) complex in Hela and MCF-7 cells and it was acetylated on a single lysine residue, Lys 685, in response to cytokine treatment [21].”
BackgroundInfluentialLevy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Murr, R., Loizou, J. I., Yang, Y.-G., Cuenin, C., Li, H., Wang, Z.-Q., & Herceg, Z. (2006) · Nature Cell Biology · doi:10.1038/ncb1343 · Cited by 613
STAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Progranulin is a mediator of the wound response
He, Z., Ong, C. H. P., Halper, J., & Bateman, A. (2003) · Nature Medicine · doi:10.1038/nm816 · Cited by 490
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Hnisz, D., Schuijers, J., Lin, C. Y., Weintraub, A. S., Abraham, B. J., Lee, T. I., Bradner, J. E., & Young, R. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.014 · Cited by 476
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation
Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., & Stark, G. R. (2005) · Cancer Research · doi:10.1158/0008-5472.939.65.3 · Cited by 405 · cited 1×
“Moreover, accumulating evidence indicates that unphosphorylated STAT3 is also capable of dimerizing and inducing the transcription of genes which mostly overlap with those modulated by phosphorylated STAT3 [29].”
BackgroundSTAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities
Davis, R. J., Welcker, M., & Clurman, B. E. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.013 · Cited by 343 · cited 1×
“The ubiquitin-ligase Fbw7 acts as a tumor suppressor, tagging a large number of proto-oncogenes for proteasomal degradation [131].”
BackgroundReversible methylation of promoter-bound STAT3 by histone-modifying enzymes
Yang, J., Huang, J., Dasgupta, M., Sears, N., Miyagi, M., Wang, B., Chance, M. R., Chen, X., Du, Y., Wang, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016147107 · Cited by 340 · cited 1×
“Besides tyrosine and serine phosphorylation, STAT3 functions in cancer cells can also be elicited by the fine tuning of other post-translational modifications (PTMs), such as methylation [18,19], ubiquitination [20], acetylation [21], SUMOylation [22], S-glutathionylation [23], and S-nitrosylation [24], through the mo…”
BackgroundOncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1×
“Likewise, direct inhibition of STAT3 itself has proven challenging because of the high similarity with STAT1, a member mostly involved in cell death and defence against pathogens [30], and the lack of suitable docking pockets for the high-affinity binding of small molecules [31].”
BackgroundWang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275 · cited 2×
“p300/CREB Regulation of Lys 685 acetylation, critical for STAT3 to form stable dimers and required for DNA binding HeLa, MCF-7 and HepG2 cells [21,57]”
BackgroundMitochondrial Stat3, the need for design thinking
Yang, R., & Rincon, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15153 · Cited by 147 · cited 1×
“A second phosphorylation on Ser727, mediated by ERK and CDK1 among others [14,15], seems to enhance the transcriptional activity of Tyr705-phosphorylated STAT3 and enable STAT3 to have the capacity to regulate cell functions in the mitochondrion [16].”
BackgroundS-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation
Butturini, E., Darra, E., Chiavegato, G., Cellini, B., Cozzolino, F., Monti, M., Pucci, P., Dell’Orco, D., & Mariotto, S. (2014) · ACS Chemical Biology · doi:10.1021/cb500407d · Cited by 82 · cited 1×
“Besides tyrosine and serine phosphorylation, STAT3 functions in cancer cells can also be elicited by the fine tuning of other post-translational modifications (PTMs), such as methylation [18,19], ubiquitination [20], acetylation [21], SUMOylation [22], S-glutathionylation [23], and S-nitrosylation [24], through the mo…”
BackgroundEpstein-Barr virus-derived EBNA2 regulates STAT3 activation
Muromoto, R., Ikeda, O., Okabe, K., Togi, S., Kamitani, S., Fujimuro, M., Harada, S., Oritani, K., & Matsuda, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.053 · Cited by 42 · cited 2×
“Later on, similar studies led to the identification of The Epstein–Barr virus (EBV)-encoded latency protein EBNA2 as a STAT3 interactor in HeLa cells [46].”
BackgroundResult
Cited by
Carlini, V., Noonan, D. M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., & Albini, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161067 · Cited by 543
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
“STAT3, a member of the STATs (Signal Transducers and Activators of Transcription) family, is generally inactivated and located in the cytoplasm (Laudisi et al., 2018).”
BackgroundNucleus, mitochondrion, or reticulum? STAT3 à La Carte
Avalle, L., & Poli, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092820 · Cited by 74
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67
Metadata
- Authors
- Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-06-16
- Volume
- 19
- Issue
- 6
- Pages
- 1787
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2808687176
- Cited by
- 127
- References
- 26
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.